What are the KDIGO (Kidney Disease: Improving Global Outcomes) stages of acute kidney injury and the components of the 5R (Risk, Resuscitation, Removal, Renal support, Review) management strategy?

KDIGO Staging of Acute Kidney Injury and the 5R Management Strategy

Acute kidney injury is diagnosed and staged using the KDIGO criteria based on serum creatinine elevation and/or urine output decline, with management structured around identifying risk, optimizing resuscitation, removing nephrotoxins, providing renal replacement therapy when indicated, and reviewing recovery.

KDIGO Definition and Staging of AKI

AKI is defined by any one of the following criteria 1, 2:

• Serum creatinine increase ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours, OR
• Serum creatinine increase ≥1.5 times baseline within 7 days, OR
• Urine output <0.5 mL/kg/hour for 6 hours

Severity Staging

The KDIGO classification uses three stages based on the worst criterion met (either creatinine or urine output) 1:

Stage 1:

• Creatinine: 1.5-1.9× baseline OR ≥0.3 mg/dL increase
• Urine output: <0.5 mL/kg/hour for 6-12 hours

Stage 2:

• Creatinine: 2.0-2.9× baseline
• Urine output: <0.5 mL/kg/hour for ≥12 hours

Stage 3:

• Creatinine: ≥3.0× baseline OR ≥4.0 mg/dL OR initiation of RRT
• Urine output: <0.3 mL/kg/hour for ≥24 hours OR anuria for ≥12 hours

Important Staging Nuances

Research suggests that Stage 1 may benefit from subdivision into Stage 1a (absolute 0.3 mg/dL increase within 48 hours) and Stage 1b (50% relative increase within 7 days), as these subgroups show markedly different mortality risks (odds ratio 4.3 vs 10.9) and length of stay (3.9 vs 6.2 days) 3. However, the current KDIGO guidelines do not formally recognize this subdivision.

The 5R Management Strategy

While the provided evidence does not explicitly detail a formal "5R strategy," the KDIGO guidelines and contemporary AKI management can be structured around five key domains:

1. Risk Assessment and Recognition

Identify high-risk patients before AKI develops:

• Preoperative creatinine elevation (independent predictor) 4
• Prolonged operative/CPB time 4
• Higher Charlson Comorbidity Index 4
• Sepsis, shock states, major surgery
• Nephrotoxic drug exposure 2

Monitor for early detection:

• Serial creatinine measurements every 48 hours in at-risk patients
• Hourly urine output monitoring in critically ill patients
• Consider biomarkers (NGAL, TIMP-2) for subclinical AKI detection, though not yet standard practice 2, 5

2. Resuscitation and Hemodynamic Optimization

Fluid management is the cornerstone of AKI prevention and treatment 6, 7:

• Use isotonic crystalloids (normal saline or balanced solutions) for volume resuscitation 7
• Avoid hydroxyethyl starch - associated with increased RRT need and mortality 7
• Maintain adequate perfusion pressure with vasopressors in vasomotor shock 2
• Avoid fluid overload - a critical pitfall where inappropriate attempts to "reverse" established AKI lead to worsening kidney function 2

Key caveat: Oliguria has multiple etiologies beyond hypovolemia; presence of early renal injury does not automatically signify need for volume replacement 2.

3. Removal of Nephrotoxic Agents

Systematically eliminate kidney injury sources 2:

• Discontinue nephrotoxic medications when possible (NSAIDs, aminoglycosides, ACE-I/ARBs in acute settings) - implemented in only 51% of patients in real-world practice 8
• Avoid iodinated contrast when alternatives exist; if necessary, use prehydration with NaCl 0.9% or bicarbonate solution 7
• Do NOT use intravenous N-acetylcysteine or prophylactic hemofiltration for contrast-associated AKI 7
• Adjust drug dosing for reduced GFR
• Conduct drug burden assessment to identify high-risk combinations 2

Common pitfall: Contrast media was still used in 35% of AKI patients despite guidelines 8, highlighting implementation gaps.

4. Renal Replacement Therapy (When Indicated)

Initiation criteria (no single optimal timing established) 2:

• Severe metabolic acidosis refractory to medical management
• Hyperkalemia unresponsive to treatment
• Fluid overload causing organ dysfunction (especially pulmonary edema)
• Uremic complications (pericarditis, encephalopathy)
• Certain poisonings/intoxications

RRT modality selection 7:

• Continuous therapies preferred in hemodynamically unstable patients
• Intermittent hemodialysis acceptable in stable patients
• Choice of modality does not impact mortality when appropriately selected

Dosing: Standard intensity RRT is sufficient; higher intensity does not improve outcomes 2.

5. Review and Recovery Monitoring

Assess for AKI resolution and long-term sequelae:

• Reassess kidney function 30-90 days post-AKI 4
• Monitor for persistent AKI - occurs in 22.5% of cases, particularly with complications 4
• Predictors of faster recovery: absence of complications, higher BMI 4
• Screen for progression to CKD - AKI survivors have increased risk
• Determine underlying cause whenever possible 1

Recovery definition remains imprecise and should encompass functional (filtration, tubular, endocrine) and structural dimensions 2.

Critical Implementation Points

Bundle approach: Early application of multiple preventive measures simultaneously (the "AKI bundle") may prevent AKI and improve outcomes 7.

Real-world adherence gaps 8:

• Hyperglycemia control: 100% implementation ✓
• Volume therapy: 82% implementation ✓
• Fluid balance management: 65% implementation
• Nephrotoxin discontinuation: 51% implementation ✗
• Inappropriate contrast use: 35% ✗

Staging drives prognosis: Progressive mortality risk increases dramatically with each stage (Stage 1a OR 4.3 → Stage 1b OR 10.9 → Stage 2 OR 40.6 → Stage 3 OR 60.0) 3, emphasizing the importance of accurate staging and early intervention.